Kai C Wollert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4736884/publications.pdf

Version: 2024-02-01

140 papers	16,317 citations	16451 64 h-index	15732 125 g-index
143 all docs	143 docs citations	143 times ranked	14706 citing authors

#	Article	IF	Citations
1	Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet, The, 2004, 364, 141-148.	13.7	2,065
2	Intracoronary Bone Marrow Cell Transfer After Myocardial Infarction. Circulation, 2006, 113, 1287-1294.	1.6	936
3	Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium. Circulation, 2005, 111, 2198-2202.	1.6	888
4	The Transforming Growth Factor-Î² Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury. Circulation Research, 2006, 98, 351-360.	4.5	551
5	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. Circulation, 2012, 126, 1596-1604.	1.6	414
6	GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine, 2011, 17, 581-588.	30.7	411
7	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	2.8	397
8	Clinical Applications of Stem Cells for the Heart. Circulation Research, 2005, 96, 151-163.	4.5	392
9	Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clinical Chemistry, 2017, 63, 140-151.	3.2	380
10	Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy. Journal of Biological Chemistry, 1996, 271, 9535-9545.	3.4	344
11	Prognostic Value of Growth-Differentiation Factor-15 in Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome. Circulation, 2007, 115, 962-971.	1.6	327
12	Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. European Heart Journal, 2009, 30, 2978-2984.	2.2	286
13	Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure. Circulation, 2010, 122, 1387-1395.	1.6	272
14	Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11363-11368.	7.1	254
15	Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay. Clinical Chemistry, 2007, 53, 284-291.	3.2	245
16	Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nature Reviews Cardiology, 2010, 7, 204-215.	13.7	237
17	Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. European Heart Journal, 2009, 30, 2346-2353.	2.2	206
18	Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Nonâ€“ST-Elevation Acute Coronary Syndrome. Circulation, 2007, 116, 1540-1548.	1.6	203

#	Article	IF	Citations
19	Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 263-275.	2.8	199
20	Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. European Heart Journal, 2007, 28, 2858-2865.	2.2	193
21	Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. European Heart Journal, 2008, 29, 2851-2858.	2.2	191
22	The reninâ€“angiotensin system and experimental heart failure. Cardiovascular Research, 1999, 43, 838-849.	3.8	186
23	Ideal Cardiovascular Health. Circulation, 2014, 130, 1676-1683.	1.6	179
24	Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nature Medicine, 2015, 21, 140-149.	30.7	168
25	The role of interleukin-6 in the failing heart. Heart Failure Reviews, 2001, 6, 95-103.	3.9	161
26	Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2015, 8, 1417-1426.	5.3	159
27	Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1018-1025.	5.6	158
28	Angiogenesis after acute myocardial infarction. Cardiovascular Research, 2021, 117, 1257-1273.	3.8	146
29	Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1655-1660.	7.1	143
30	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 203-210.	2.4	138
31	Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy. Circulation, 2003, 107, 798-802.	1.6	135
32	Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 534-541.	5.6	134
33	Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. European Journal of Endocrinology, 2012, 167, 671-678.	3.7	134
34	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	2.2	133
35	Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. Journal of Clinical Investigation, 2011, 121, 703-714.	8.2	133
36	Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes. Hypertension, 2002, 39, 87-92.	2.7	128

#	Article	IF	Citations
37	Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. European Heart Journal, 2006, 27, 929-935.	2.2	124
38	Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. European Heart Journal, 2016, 38, ehw333.	2.2	115
39	Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2009, 2, 286-292.	5.1	113
40	GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men. PLoS ONE, 2013, 8, e78797.	2.5	108
41	Clinical and Genetic Correlates of Growth Differentiation Factor 15 in the Community. Clinical Chemistry, 2012, 58, 1582-1591.	3.2	106
42	The Cardiac Fas (APO-1/CD95) Receptor/Fas Ligand System. Circulation, 2000, 101, 1172-1178.	1.6	104
43	Interference of antihypertrophic molecules and signaling pathways with the Ca2+?calcineurin?NFAT cascade in cardiac myocytes. Cardiovascular Research, 2004, 63, 450-457.	3.8	97
44	Multiple marker approach to risk stratification in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 3024-3031.	2.2	97
45	Change in Growth Differentiation Factor 15 Concentrations over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals. Clinical Chemistry, 2013, 59, 1091-1098.	3.2	96
46	Potential novel pharmacological therapies for myocardial remodelling. Cardiovascular Research, 2008, 81, 519-527.	3.8	95
47	Growth Differentiation Factor 15 in Heart Failure: An Update. Current Heart Failure Reports, 2012, 9, 337-345.	3.3	95
48	Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. Clinical Chemistry, 2013, 59, 1613-1620.	3.2	91
49	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal, 2017, 38, 2936-2943.	2.2	91
50	Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development. Journal of Molecular Medicine, 1997, 75, 492-501.	3.9	89
51	Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. European Heart Journal, 2012, 33, 1095-1104.	2.2	88
52	C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. Circulation, 2019, 139, 1798-1812.	1.6	88
53	Single L-type Ca2+ channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice. Cardiovascular Research, 2003, 60, 268-277.	3.8	86
54	Relation between soluble ST2, growth differentiation factorâ€“15, and high-sensitivity troponin I and incident atrial fibrillation. American Heart Journal, 2014, 167, 109-115.e2.	2.7	85

#	Article	IF	Citations
55	Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Genetics, 2010, 3, 88-96.	5.1	82
56	Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Failure Reviews, 2002, 7, 317-325.	3.9	81
57	cGMP-dependent Protein Kinase Type I Inhibits TAB1-p38 Mitogen-activated Protein Kinase Apoptosis Signaling in Cardiac Myocytes. Journal of Biological Chemistry, 2006, 281, 32831-32840.	3.4	79
58	C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure. Circulation Research, 2017, 120, 66-77.	4.5	77
59	Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecologic Oncology, 2010, 118, 237-243.	1.4	74
60	Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages inÂthe Community. JACC: Heart Failure, 2016, 4, 808-815.	4.1	72
61	Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide. Circulation, 2003, 107, 1424-1432.	1.6	69
62	Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study. European Journal of Echocardiography, 2010, 11, 165-171.	2.3	68
63	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet, The, 2016, 388, 1903-1911.	13.7	68
64	Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. European Heart Journal, 2008, 29, 2327-2335.	2.2	66
65	Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening. Journal of the American Heart Association, 2013, 2, e000399.	3.7	66
66	Mesenchymal Stem Cells for Myocardial Infarction. Circulation, 2005, 112, 151-153.	1.6	64
67	Growth-Differentiation Factor-15 in Heart Failure. Heart Failure Clinics, 2009, 5, 537-547.	2.1	64
68	Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay. Clinical Chemistry, 2009, 55, 1794-1800.	3.2	63
69	Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer. Clinical Cancer Research, 2011, 17, 4825-4833.	7.0	61
70	Continuous WNT Control Enables Advanced hPSC Cardiac Processing and Prognostic Surface Marker Identification in Chemically Defined Suspension Culture. Stem Cell Reports, 2019, 13, 366-379.	4.8	61
71	Cell-based therapy for heart failure. Current Opinion in Cardiology, 2006, 21, 234-239.	1.8	60
72	Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction. Circulation, 2011, 123, 504-514.	1.6	60

#	Article	IF	Citations
73	Targeting post-infarct inflammation by PET imaging: comparison of 68Ga-citrate and 68Ga-DOTATATE with 18F-FDG in a mouse model. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 317-327.	6.4	60
74	Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. American Heart Journal, 2010, 160, 88-94.	2.7	58
75	Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. Journal of Molecular Medicine, 2012, 90, 361-369.	3.9	57
76	Targeting Amino Acid Metabolism for Molecular Imaging of Inflammation Early After Myocardial Infarction. Theranostics, 2016, 6, 1768-1779.	10.0	56
77	Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes. Cardiovascular Research, 2004, 63, 545-552.	3.8	55
78	Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus. Hypertension, 2009, 54, 106-112.	2.7	55
79	Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke. Stroke, 2015, 46, 2568-2575.	2.0	54
80	Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. European Heart Journal, 2020, 41, 3564-3575.	2.2	52
81	Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. British Journal of Pharmacology, 2003, 140, 1227-1236.	5.4	51
82	Incremental Prognostic Value of Biomarkers beyond the GRACE (Global Registry of Acute Coronary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Chemistry, 2013, 59, 1497-1505.	3.2	50
83	Biomarkers for characterization of heart failure â€“ Distinction of heart failure with preserved and reduced ejection fraction. International Journal of Cardiology, 2017, 227, 272-277.	1.7	49
84	Inactivation of Sox9 in fibroblasts reduces cardiac fibrosis and inflammation. JCI Insight, 2019, 4, .	5.0	47
85	Nitric oxide and the enigma of cardiac hypertrophy. BioEssays, 2004, 26, 608-615.	2.5	46
86	Identification of Follistatin-Like 1 by Expression Cloning as an Activator of the Growth Differentiation Factor 15 Gene and a Prognostic Biomarker in Acute Coronary Syndrome. Clinical Chemistry, 2012, 58, 1233-1241.	3.2	46
87	Growth Differentiation Factor-15: a New Biomarker in Cardiovascular Disease. Herz, 2009, 34, 594-599.	1.1	45
88	Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. American Heart Journal, 2015, 170, 821-829.	2.7	43
89	Growth-differentiation factor-15 in cardiovascular disease. Basic Research in Cardiology, 2007, 102, 412-415.	5.9	39
90	Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, S65-S68.	3.3	36

#	Article	IF	Citations
91	Growth Differentiation Factor 15 Plasma Levels and Outcome after Ischemic Stroke. Cerebrovascular Diseases, 2011, 32, 72-78.	1.7	35
92	Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 45-51.	1.2	35
93	Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. International Journal of Cardiology, 2014, 172, 356-363.	1.7	35
94	An Automated Assay for Growth Differentiation Factor 15. journal of applied laboratory medicine, The, 2017, 1, 510-521.	1.3	35
95	Heparan Sulfateâ€“Editing Extracellular Sulfatases Enhance VEGF Bioavailability for Ischemic Heart Repair. Circulation Research, 2019, 125, 787-801.	4.5	35
96	Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis. Basic Research in Cardiology, 2021, 116, 26.	5.9	34
97	Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science, 2022, 376, 1343-1347.	12.6	34
98	Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. International Journal of Cardiology, 2013, 166, 729-735.	1.7	32
99	EMC10 (Endoplasmic Reticulum Membrane Protein Complex Subunit 10) Is a Bone Marrowâ€“Derived Angiogenic Growth Factor Promoting Tissue Repair After Myocardial Infarction. Circulation, 2017, 136, 1809-1823.	1.6	32
100	Cardiac iron concentration in relation to systemic iron status and disease severity in nonâ€ischaemic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 2038-2046.	7.1	32
101	Cell therapy for acute myocardial infarction. Current Opinion in Pharmacology, 2008, 8, 202-210.	3.5	30
102	Radionuclide Image-Guided Repair ofÂtheÂHeart. JACC: Cardiovascular Imaging, 2020, 13, 2415-2429.	5.3	29
103	Targeting of Extracellular RNA Reduces Edema Formation and Infarct Size and Improves Survival After Myocardial Infarction in Mice. Journal of the American Heart Association, 2017, 6, .	3.7	27
104	Myeloid-Derived Growth Factor Protects Against Pressure Overloadâ€“Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca ²⁺ -ATPase Expression in Cardiomyocytes. Circulation, 2021, 144, 1227-1240.	1.6	27
105	Skeletal muscle derived Musclin protects the heart during pathological overload. Nature Communications, 2022, 13, 149.	12.8	27
106	Targeting calcineurin and associated pathways in cardiac hypertrophy and failure. Expert Opinion on Therapeutic Targets, 2005, 9, 963-973.	3.4	24
107	Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. Clinical Chemistry, 2014, 60, 1402-1408.	3.2	24
108	Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure. Journal of Nuclear Medicine, 2020, 61, 590-596.	5.0	23

#	Article	IF	Citations
109	Crystal structure and receptor-interacting residues of MYDGF â€" a protein mediating ischemic tissue repair. Nature Communications, 2019, 10, 5379.	12.8	19
110	¹¹C-Methionine PET Identifies Astroglia Involvement in Heartâ€"Brain Inflammation Networking After Acute Myocardial Infarction. Journal of Nuclear Medicine, 2020, 61, 977-980.	5.0	18
111	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. Clinical Chemistry, 2016, 62, 485-493.	3.2	17
112	<scp>TIP</scp> 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation. EMBO Molecular Medicine, 2019, 11, e10018.	6.9	17
113	Image-guided therapies for myocardial repair: concepts and practical implementation. European Heart Journal Cardiovascular Imaging, 2013, 14, 741-751.	1.2	16
114	Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. International Journal of Cardiology, 2017, 232, 155-159.	1.7	15
115	Biomarkers for the prediction of venous thromboembolism in the community. Thrombosis Research, 2016, 145, 34-39.	1.7	14
116	GDFâ€15 in heart failure: providing insight into endâ€organ dysfunction and its recovery?. European Journal of Heart Failure, 2012, 14, 1191-1193.	7.1	13
117	Plasma Concentrations of Myeloid-Derived Growth Factor in Healthy Individuals and Patients with Acute Myocardial Infarction as Assessed by Multiple Reaction Monitoring-Mass Spectrometry. Analytical Chemistry, 2019, 91, 1302-1308.	6.5	13
118	Pleiotropic cardiac functions controlled by ischemia-induced lncRNA H19. Journal of Molecular and Cellular Cardiology, 2020, 146, 43-59.	1.9	12
119	Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. Critical Care, 2013, 17, 173.	5.8	11
120	Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. Clinical Research in Cardiology, 2017, 106, 401-410.	3.3	11
121	Reg3Î² is associated with cardiac inflammation and provides prognostic information in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 258, 7-13.	1.7	9
122	Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1353-1368.	3.3	8
123	Iron and atherosclerosis: too much of a good thing can be bad. European Heart Journal, 2020, 41, 2696-2698.	2.2	7
124	The role of stem cells in the post-MI patient. Current Heart Failure Reports, 2007, 4, 198-203.	3.3	6
125	Tailored therapy for heart failure: the role of biomarkers. European Heart Journal, 2012, 33, 2246-2248.	2.2	6
126	Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock. Journal of Cardiac Failure, 2019, 25, 894-901.	1.7	6

#	Article	IF	Citations
127	Bone marrow mononuclear cell therapy for acute myocardial infarction: we know what we want, but we just donâ€™t know how yet. Heart, 2015, 101, 337-338.	2.9	4
128	Regulation of Cardiac Remodeling by Nitric Oxide: Focus on Cardiac Myocyte Hypertrophy and Apoptosis. , 2004, , 71-79.		2
129	Growth differentiation factorâ€15 reveals the dark side of heart failure. European Journal of Heart Failure, 2018, 20, 1710-1712.	7.1	2
130	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. Clinical Research in Cardiology, 2020, 109, 539-548.	3.3	2
131	Circulating growth factors and cardiac remodeling in the community: The Framingham Heart Study. International Journal of Cardiology, 2021, 329, 217-224.	1.7	2
132	A mouse model of cardiogenic shock. Cardiovascular Research, 2021, 117, 2414-2415.	3.8	2
133	Monitoring of Bone Marrow Cell Homing in the Infarcted Human Myocardium by PET.. Blood, 2004, 104, 2696-2696.	1.4	2
134	Follistatin-Like 1. JACC Basic To Translational Science, 2016, 1, 222-223.	4.1	1
135	Ischaemic risk and bleeding risk in acute coronary syndrome: still inseparable. European Heart Journal, 2016, 37, 1334-1336.	2.2	1
136	Cardioprotection vs. regeneration: the case of extracellular vesicle-derived microRNAs. Basic Research in Cardiology, 2021, 116, 20.	5.9	1
137	Nitric oxide as a negative regulator of cardiac myocyte hypertrophy - Signaling pathways and novel downstream targets -. BMC News and Views, 2003, 3, .	0.0	0
138	Bone Marrow Cell Therapy After Myocardial Infarction: What have we Learned from the Clinical Trials and Where Are We Going?. , 2011, , 111-129.		0
139	Growth factor therapy to prevent postinfarction heart failure. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY4-4.	0.0	0
140	Response by Wollert to Letter Regarding Article, â€œMyeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failureâ€• Circulation, 2022, 145, e770.	1.6	0